FDA approves taletrectinib for ROS1-positive non-small cell lung cancer
On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small ...
IBTROZI for the Treatment of Non-small Cell Lung Cancer, US
2 days ago · Credit: Nuvation Bio, Inc. IBTROZI ™ (taletrectinib) is a tyrosine kinase inhibitor indicated for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) …
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI ...
Jun 11, 2025 · NEW YORK-- (BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced …
FDA Approves Taletrectinib for ROS1-Positive NSCLC Treatment
Jun 13, 2025 · FDA approval of Taletrectinib for ROS1 positive Non Small Cell Lung Cancer Taletrectinib was approved by the U.S. Food and Drug Administration (FDA) on June 11, 2025, for …
Taletrectinib Increases Already Broad Selection of ROS1+ NSCLC ...
On June 11, 2025, the FDA approved taletrectinib (Ibtrozi) for the treatment of patients with locally advanced or metastatic ROS1 -positive non–small cell lung cancer (NSCLC). 1 In the wake of this …
FDA Approves Ibtrozi (taletrectinib) for Advanced ROS1-Positive Non ...
Ibtrozi is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor therapy approved for the treatment of adult patients with advanced ROS1-positive non-small cell lung …
FDA Approves Ibtrozi for ROS1-Positive NSCLC
Jun 11, 2025 · The FDA approved taletrectinib (Ibtrozi, Nuvation Bio), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI ...
Sep 30, 2025 · IBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC). IMPORTANT SAFETY INFORMATION FOR …
FDA Approves Talectrectinib (Ibtrozi) for ROS1-Positive Lung Cancer
On June 11, 2025, the U.S. Food and Drug Administration (FDA) approved taletrectinib (Ibtrozi), a new targeted therapy for adults with locally advanced or metastatic ROS1-positive non-small cell lung …
NCCN Guidelines Now Recommend Taletrectinib for ROS1+ NSCLC
Jun 25, 2025 · The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancers (NSCLC) have added taletrectinib (Ibtrozi) as a preferred …